OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Immunology Immunotherapy is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells	129
Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells	118
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer	100
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model	98
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML c	89
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies	80
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma	65
Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer	65
A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes	64
OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression	55
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers	50
Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter ret	50
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study	49
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study	49
Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19	47
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma	45
Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma	44
High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach	44
Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma	44
Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and m	43
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition	42
Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist	41
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas	40
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study	40
Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer	37

Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion	37
Establishment of a mechanism-based in vitro coculture assay for evaluating the efficacy of immune checkpoint inhibitors	36
Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8+ T cells in clear cell renal cell carcinoma	35
Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer	35
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors	33
Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma	32
Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens	32
A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs	32
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents	32